BG107157A - Sustained release beadlets containing stavudine - Google Patents
Sustained release beadlets containing stavudineInfo
- Publication number
- BG107157A BG107157A BG107157A BG10715702A BG107157A BG 107157 A BG107157 A BG 107157A BG 107157 A BG107157 A BG 107157A BG 10715702 A BG10715702 A BG 10715702A BG 107157 A BG107157 A BG 107157A
- Authority
- BG
- Bulgaria
- Prior art keywords
- beadlets
- stavudine
- extrusion
- coated
- magnesium stearate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19358800P | 2000-03-30 | 2000-03-30 | |
PCT/US2001/010078 WO2001074329A2 (en) | 2000-03-30 | 2001-03-29 | Sustained release beadlets containing stavudine |
Publications (1)
Publication Number | Publication Date |
---|---|
BG107157A true BG107157A (en) | 2003-06-30 |
Family
ID=22714247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG107157A BG107157A (en) | 2000-03-30 | 2002-09-30 | Sustained release beadlets containing stavudine |
Country Status (26)
Country | Link |
---|---|
US (1) | US7135465B2 (es) |
EP (1) | EP1267879A2 (es) |
JP (1) | JP2003528905A (es) |
KR (1) | KR20030011805A (es) |
CN (1) | CN1187052C (es) |
AR (1) | AR027748A1 (es) |
AU (1) | AU2001249591A1 (es) |
BG (1) | BG107157A (es) |
BR (1) | BR0109602A (es) |
CA (1) | CA2404687A1 (es) |
CZ (1) | CZ20023003A3 (es) |
EE (1) | EE200200564A (es) |
GE (1) | GEP20043285B (es) |
HU (1) | HUP0302631A2 (es) |
IL (1) | IL151475A0 (es) |
LT (1) | LT5045B (es) |
LV (1) | LV12939B (es) |
MX (1) | MXPA02009534A (es) |
NO (1) | NO20024645L (es) |
NZ (1) | NZ522250A (es) |
PE (1) | PE20011179A1 (es) |
PL (1) | PL366089A1 (es) |
RU (1) | RU2239435C2 (es) |
SK (1) | SK12822002A3 (es) |
WO (1) | WO2001074329A2 (es) |
ZA (1) | ZA200207760B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
KR20050047507A (ko) * | 2002-06-27 | 2005-05-20 | 시락 아게 | 구형 펠렛 제제 |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN100548309C (zh) * | 2004-11-24 | 2009-10-14 | 东北制药总厂 | 司他夫定缓释片剂 |
TW201414495A (zh) | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Hiv-感染之預防 |
AU2006259619A1 (en) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
AU2006286314A1 (en) * | 2005-08-31 | 2007-03-08 | Cipla Limited | Pharmaceutical combinations containing lamivudine, stavudine and nevirapine |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
WO2007112579A1 (en) * | 2006-04-03 | 2007-10-11 | Isa Odidi | Drug delivery composition |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
CN102319181B (zh) * | 2011-09-08 | 2014-07-16 | 广东大华农动物保健品股份有限公司 | 一种微囊型动物药品的包被工艺 |
US20140271893A1 (en) * | 2013-03-15 | 2014-09-18 | Mcneil-Ppc, Inc. | Coated phenylephrine particles and use thereof in pharmaceutical formulations |
JP2017522321A (ja) * | 2014-07-17 | 2017-08-10 | ダウ グローバル テクノロジーズ エルエルシー | エチルセルロース分散系とフィルム |
CN105511174A (zh) * | 2016-01-05 | 2016-04-20 | 深圳市华星光电技术有限公司 | 液晶显示面板和显示装置 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671963A (en) | 1983-10-28 | 1987-06-09 | Germino Felix J | Stearate treated food products |
US4670270A (en) | 1984-05-07 | 1987-06-02 | Germino Felix J | Stearate treated food products |
US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US4978655A (en) * | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
DE69231499T2 (de) | 1991-12-30 | 2001-05-03 | Fmc Corp | Zusammensetzung auf der basis von mikrokristalliner zellulose für die herstellung von kugelförmigen teilchen |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
FI101039B (fi) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
GB9403449D0 (en) | 1994-02-23 | 1994-04-13 | Wellcome Found | Therapeutic benzonitriles |
MX9603909A (es) | 1994-03-07 | 1997-03-29 | Vertex Pharma | Derivados de sulfonamida como inhibidores de proteasa aspartilo. |
KR19980701739A (ko) | 1995-02-23 | 1998-06-25 | 디르크 반테 | 신경보호제로서 융합된 벤조티아졸의 용도 |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
EE9800176A (et) | 1995-12-15 | 1998-12-15 | Cryopreservation Technologies Cc | Koostis organite külmsäilitamiseks ning viirus- ja bakterinfektsioonide ravimiseks |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US5883252A (en) | 1996-01-26 | 1999-03-16 | Vertex Pharmaceuticals Incorporated | Aspartyl protease inhibitors |
US5766623A (en) | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US5780055A (en) | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
US5905068A (en) | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6110498A (en) | 1996-10-25 | 2000-08-29 | Shire Laboratories, Inc. | Osmotic drug delivery system |
US5962462A (en) | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
ES2234139T3 (es) | 1997-08-11 | 2005-06-16 | Alza Corporation | Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica. |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
AU9496798A (en) * | 1997-09-19 | 1999-04-05 | Shire Laboratories, Inc. | Solid solution beadlet |
US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
US6013644A (en) | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
KR20010032841A (ko) | 1997-12-19 | 2001-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물 |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
AU4716299A (en) | 1998-06-24 | 2000-01-10 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
NZ514558A (en) | 1999-03-31 | 2004-02-27 | Uaf Technologies And Res Llc | Viral treatment |
US6136835A (en) | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
-
2001
- 2001-03-29 MX MXPA02009534A patent/MXPA02009534A/es not_active Application Discontinuation
- 2001-03-29 US US09/821,103 patent/US7135465B2/en not_active Expired - Lifetime
- 2001-03-29 IL IL15147501A patent/IL151475A0/xx unknown
- 2001-03-29 NZ NZ522250A patent/NZ522250A/en unknown
- 2001-03-29 BR BR0109602-8A patent/BR0109602A/pt not_active IP Right Cessation
- 2001-03-29 PL PL01366089A patent/PL366089A1/xx not_active Application Discontinuation
- 2001-03-29 EE EEP200200564A patent/EE200200564A/xx unknown
- 2001-03-29 GE GEAP20016630A patent/GEP20043285B/en unknown
- 2001-03-29 KR KR1020027012769A patent/KR20030011805A/ko not_active Application Discontinuation
- 2001-03-29 WO PCT/US2001/010078 patent/WO2001074329A2/en not_active Application Discontinuation
- 2001-03-29 EP EP01922832A patent/EP1267879A2/en not_active Withdrawn
- 2001-03-29 RU RU2002126540/15A patent/RU2239435C2/ru not_active IP Right Cessation
- 2001-03-29 HU HU0302631A patent/HUP0302631A2/hu unknown
- 2001-03-29 CN CNB018074405A patent/CN1187052C/zh not_active Expired - Fee Related
- 2001-03-29 CA CA002404687A patent/CA2404687A1/en not_active Abandoned
- 2001-03-29 AU AU2001249591A patent/AU2001249591A1/en not_active Abandoned
- 2001-03-29 AR ARP010101516A patent/AR027748A1/es unknown
- 2001-03-29 SK SK1282-2002A patent/SK12822002A3/sk unknown
- 2001-03-29 JP JP2001572074A patent/JP2003528905A/ja active Pending
- 2001-03-29 CZ CZ20023003A patent/CZ20023003A3/cs unknown
- 2001-03-30 PE PE2001000297A patent/PE20011179A1/es not_active Application Discontinuation
-
2002
- 2002-09-06 LT LT2002099A patent/LT5045B/lt not_active IP Right Cessation
- 2002-09-26 ZA ZA200207760A patent/ZA200207760B/en unknown
- 2002-09-27 NO NO20024645A patent/NO20024645L/no not_active Application Discontinuation
- 2002-09-30 BG BG107157A patent/BG107157A/xx unknown
- 2002-10-25 LV LVP-02-187A patent/LV12939B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1267879A2 (en) | 2003-01-02 |
SK12822002A3 (sk) | 2003-02-04 |
KR20030011805A (ko) | 2003-02-11 |
AR027748A1 (es) | 2003-04-09 |
NO20024645D0 (no) | 2002-09-27 |
LT5045B (lt) | 2003-08-25 |
CN1187052C (zh) | 2005-02-02 |
RU2239435C2 (ru) | 2004-11-10 |
EE200200564A (et) | 2004-06-15 |
AU2001249591A1 (en) | 2001-10-15 |
PE20011179A1 (es) | 2001-12-06 |
IL151475A0 (en) | 2003-04-10 |
GEP20043285B (en) | 2004-07-26 |
JP2003528905A (ja) | 2003-09-30 |
NO20024645L (no) | 2002-09-27 |
NZ522250A (en) | 2004-09-24 |
WO2001074329A2 (en) | 2001-10-11 |
PL366089A1 (en) | 2005-01-24 |
MXPA02009534A (es) | 2003-05-14 |
US20020002147A1 (en) | 2002-01-03 |
LT2002099A (en) | 2003-04-25 |
US7135465B2 (en) | 2006-11-14 |
LV12939B (en) | 2003-04-20 |
CN1420774A (zh) | 2003-05-28 |
RU2002126540A (ru) | 2004-03-27 |
BR0109602A (pt) | 2004-06-29 |
HUP0302631A2 (hu) | 2003-11-28 |
CZ20023003A3 (cs) | 2002-11-13 |
CA2404687A1 (en) | 2001-10-11 |
WO2001074329A3 (en) | 2002-05-10 |
ZA200207760B (en) | 2004-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG107157A (en) | Sustained release beadlets containing stavudine | |
MXPA03006364A (es) | TRATAMIENTO DE PERTURBACIONES DEL SUEnO. | |
NO20092274L (no) | Ansamycinformuleringer og fremgangsmater for anvendelse derav | |
RS56252B1 (sr) | Jednodnevne formulacije oksikodona | |
WO2001001973A3 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
BR0310006A (pt) | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos | |
TW200531688A (en) | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents | |
BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
PL374443A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
EP0870502A3 (en) | Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis | |
HUP0001104A2 (hu) | Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére | |
BR0114276A (pt) | Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo | |
HUP0102987A2 (hu) | Hatóanyagként asztrocita funkciójavító szert tartalmazó készítmény Parkinson-kór kezelésére | |
TW200736220A (en) | Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents | |
WO2007054139A3 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
TW200612914A (en) | Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents | |
MXPA05010135A (es) | Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos. | |
SE9704770D0 (sv) | New use | |
TW200602329A (en) | Novel diazine derivatives, their manufacture and use as pharmaceutical agents | |
TW200626149A (en) | Tricycles, their manufacture and use as pharmaceutical agents | |
NO984974L (no) | Middel som forbedrer pulmonar sirkulasjon | |
MXPA05011671A (es) | Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos. |